OVA (257-264) Variant E1 is an engineered ovalbumin epitope used to probe the impact of residue substitutions on antigen presentation. Its sequence supports systematic evaluation of MHC anchor preferences. Researchers employ it to study TCR sensitivity to altered side-chain chemistry. The peptide aids fine-tuned epitope engineering studies.
CAT No: O05011
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
2. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
5. Implications of ligand-receptor binding kinetics on GLP-1R signalling
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More